ProBioGen AG, Herbert-Bayer-Straße 8, 13086, Berlin, Germany.
Sartorius Stedim Cellca GmbH, Erwin-Rentschler-Str 21, 88471, Laupheim, Germany.
Virol Sin. 2020 Apr;35(2):212-226. doi: 10.1007/s12250-019-00176-3. Epub 2019 Dec 12.
Vectored vaccines based on highly attenuated modified vaccinia Ankara (MVA) are reported to be immunogenic, tolerant to pre-existing immunity, and able to accommodate and stably maintain very large transgenes. MVA is usually produced on primary chicken embryo fibroblasts, but production processes based on continuous cell lines emerge as increasingly robust and cost-effective alternatives. An isolate of a hitherto undescribed genotype was recovered by passage of a non-plaque-purified preparation of MVA in a continuous anatine suspension cell line (CR.pIX) in chemically defined medium. The novel isolate (MVA-CR19) replicated to higher infectious titers in the extracellular volume of suspension cultures and induced fewer syncytia in adherent cultures. We now extend previous studies with the investigation of the point mutations in structural genes of MVA-CR19 and describe an additional point mutation in a regulatory gene. We furthermore map and discuss an extensive rearrangement of the left telomer of MVA-CR19 that appears to have occurred by duplication of the right telomer. This event caused deletions and duplications of genes that may modulate immunologic properties of MVA-CR19 as a vaccine vector. Our characterizations also highlight the exceptional genetic stability of plaque-purified MVA: although the phenotype of MVA-CR19 appears to be advantageous for replication, we found that all genetic markers that differentiate wildtype and MVA-CR19 are stably maintained in passages of recombinant viruses based on either wildtype or MVA-CR.
基于高度减毒的改良安卡拉痘苗病毒(MVA)的载体疫苗被报道具有免疫原性、耐受预先存在的免疫、并能够容纳和稳定维持非常大的转基因。MVA 通常在原代鸡胚成纤维细胞上生产,但基于连续细胞系的生产工艺作为越来越强大和具有成本效益的替代方案出现。通过在化学定义的培养基中,用非空斑纯化的 MVA 制剂在连续禽源悬浮细胞系(CR.pIX)中转代,回收了一种迄今尚未描述的基因型的分离株。新型分离株(MVA-CR19)在悬浮培养物的细胞外体积中复制到更高的感染滴度,并在贴壁培养物中诱导更少的合胞体。我们现在扩展了以前对 MVA-CR19 结构基因点突变的研究,并描述了一个调节基因中的额外点突变。我们还定位并讨论了 MVA-CR19 左端粒的广泛重排,该重排似乎是通过右端粒的复制发生的。该事件导致了可能调节 MVA-CR19 作为疫苗载体的免疫特性的基因缺失和重复。我们的表征还突出了纯化斑块的 MVA 的异常遗传稳定性:尽管 MVA-CR19 的表型似乎有利于复制,但我们发现,区分野生型和 MVA-CR19 的所有遗传标记都在基于野生型或 MVA-CR 的重组病毒的传代中稳定维持。